Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 45

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 45
---
9 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject to and will be
available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire, terminate,
or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2023
Plan.

The Company granted options
to purchase zero0 and 366,500
shares of Common Stock to employees with a three-year vesting period during the three and nine months ended March 31, 2024,
respectively under the 2019 and 2023 Plan. The Company granted options to purchase 15,000and 193,000shares of Common Stock to employees with a three-year vesting period during the three and nine months ended March 31, 2023, respectively under the 2019 Plan.

During the three and nine
months ended March 31, 2024, respectively, the Company granted options to purchase zero0 shares of Common Stock to employees with a six-month vesting period under the 2023 Plan. During the three and nine
months ended March 31, 2023, the Company granted options to purchase zero 0
and 184,800
issued and 018,960
forfeited shares of Common Stock to employees with a six-month vesting period, respectively under the 2019 Plan.

During the three and nine
months ended March 31, 2024, respectively, the Company granted options to purchase zero 0
shares of Common Stock to employees with a one-year vesting period under the 2023 Plan. During the three and nine months ended March
31, 2023, the Company granted options to purchase zero 0
and 73,200
issued and 0 12,640
forfeited shares of Common Stock to employees with a one-year vesting period, respectively under the 2019 Plan.

During the three and nine months
ended March 31, 2024, the Company granted options to purchase 28,196 and 371,595 shares of Common Stock, to the Board of Directors and
Scientific Advisory Board Members with a one-year vesting period under the 2023 Plan and the 2019 Plan, respectively. During the three and nine months ended March 31, 2023, the Company granted options to purchase 64,655and 275